Boehringer Launches Switched Flomax Relief MR For BPH In U.K.

Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says

More from Archive

More from Pink Sheet